Stock comparison
Collegium Pharmaceutical
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
COLL
Collegium Pharmaceutical
Market cap
$1.11B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | COLL | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 46D | 79B | HALO |
| Benjamin Graham | 62D | 83A | HALO |
| Philip Fisher | 40D | 65B | HALO |
| Peter Lynch | 53D | 53D | Tie |
| Joel Greenblatt | 28F | 40D | HALO |
| Charlie Munger | 44D | 80C | HALO |
| Terry Smith | 43D | 84A | HALO |
Side-by-side metrics
| Metric | COLL | HALO |
|---|---|---|
| Market cap | $1.11B | $8.1B |
| P/E (TTM) | 15.5x | 24.0x |
| EV/EBIT | 9.1x | 10.2x |
| ROIC (TTM) | 10.51% | 23.65% |
| Gross margin | 60.68% | 81.24% |
| Net margin | 9.41% | 23.13% |
| Revenue CAGR 5y | 29.58% | 33.23% |
| EPS CAGR 5y | -0.86% | -1.98% |
| Debt / Equity | 2.6x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
COLL leads on
- EPS CAGR 5y-0.86%vs -1.98%+56%
- P/E (TTM)15.5xvs 24.0x+36%
- EV/EBIT9.1xvs 10.2x+10%
HALO leads on
- Market cap$8.1Bvs $1.11B+86%
- Debt / Equity1.0xvs 2.6x+63%
- Net margin23.13%vs 9.41%+59%
- ROIC (TTM)23.65%vs 10.51%+56%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.